Clinical trials for a novel prostate cancer therapy showed promising results, but the net loss widened to -56,079 TSEK and liquidity remains a concern. Additional financing is needed to continue clinical development, with auditors highlighting material uncertainty about going concern.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.